Clobetasol propionate oral - AFYX Therapeutics
Alternative Names: AFYX-005; Rivelin® Clobetasol patch; Rivelin®-CLOLatest Information Update: 31 Mar 2025
At a glance
- Originator Dermtreat
- Developer AFYX Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antiulcers; Fluorinated steroids; Glucocorticoids; Halogenated hydrocarbons; Propionates
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Lichen planus; Vulvar lichen sclerosus
- Phase I Aphthous stomatitis
Most Recent Events
- 31 Mar 2025 Phase-I clinical trials in Aphthous stomatitis (Topical) prior to March 2025 (AFYX Therapeutics Pipeline, March 2025)
- 31 Mar 2025 Phase-II clinical trials in Vulvar lichen sclerosus (Topical) prior to March 2025 (AFYX Therapeutics Pipeline, March 2025)
- 03 May 2023 Preclinical trials in Aphthous stomatitis in Denmark (Topical) (AFYX Therapeutics pipeline, May 2023)